FDA Approves COLISTIMETHATE — Fresenius Kabi USA, LLC
Fresenius Kabi USA, LLC announced the approval of the intramuscular formulation for its generic Colistimethate Sodium (ANDA065364), expanding the therapeutic landscape for this critical antibiotic. This approval allows for an alternative intramuscular delivery route, potentially increasing patient adherence and creating additional revenue opportunities for the company within the critically scarce colistin market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed